Section Arrow
Quote
RAPP.NASDAQ
- Rapport Therapeutics Inc.
Quotes are at least 15-min delayed:2026/04/22 11:53 EDT
Regular Hours
Last
 36.41
-0.54 (-1.46%)
Day High 
37.875 
Prev. Close
36.95 
1-M High
40.92 
Volume 
59.73K 
Bid
36.39
Ask
36.5
Day Low
36.33 
Open
37.38 
1-M Low
26.96 
Market Cap 
1.77B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 36.29 
20-SMA 33.35 
50-SMA 30.58 
52-W High 42.2685 
52-W Low 7.73 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.86/-3.56
Enterprise Value
1.77B
Balance Sheet
Book Value Per Share
10.14
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.2138+0.017+8.64%-- 
REPLReplimune Group2.165+0.305+16.40%-- 
IOVAIovance Biotherapeutics3.44-0.26-7.03%-- 
TOVXTheriva Biologics Inc0.358801+0.020101+5.93%0.09PE
OCGNOcugen1.695-0.075-4.24%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.